Accéder au contenu
Merck

Neurotransmitter-mediated anxiogenic action of PACAP-38 in rats.

Behavioural brain research (2014-12-30)
G Telegdy, A Adamik
RÉSUMÉ

The action of PACAP-38 was studied by measuring the anxiogenic-anxiolytic behavior of rats in an elevated plus maze. PACAP-38 was administered into the lateral brain ventricle and the behavior of the animals was measured 3h later. The possible involvement of transmitters was measured by pretreating the animals with receptor blockers which alone did not influence the task, but in the doses used were effective with other neuropeptides. The receptor antagonist PACAP 6-38 (a PAC 1/VPAC2 receptor antagonist of PACAP-38 receptor), haloperidol (a non-selective dopamine receptor antagonist), phenoxybenzamine (an α1/α2β-adrenergic receptor antagonist), propranolol(a β-adrenergic receptor antagonist), bicuculline (a gamma-aminobutyric acid subunit A receptor antagonist), methysergide (a nonselective 5-HT2 serotonergic receptor antagonist), atropine (a nonselective muscarinic acetylcholine receptor antagonist), naloxone (a nonselective opioid receptor antagonist) and nitro-l-arginine which acts by blocking the enzyme nitric oxide synthase, thereby blocking the nitric oxide synthesis, were tested. The following parameters were measured: the time spent in open arms/the time spent in total entries. PACAP-38 decreased the ratio of time spent in open arms to the time spent in total entries, indicating anxiogenic action. The total number of entries was not altered significantly either by PACAP-38 or by the receptor blockers. The following receptor blockers diminished the action of PACAP-38: PACAP 6-38,haloperidol, methysergide, naloxone and nitro-l-arginine. Pretreatment with atropine, phenoxybenzamine, propranolol and bicuculline did not influence the action of PACAP-38 on the time spent in open arms. The results demonstrate that PACAP-38 administered into the lateral brain ventricle exerted anxiogenic action at 3 h following treatment. Pretreatment of the animals with various receptor blockers indicated that a nonselective dopaminergic receptor antagonist, 5HT2 serotonergic and opioid receptors, nitric oxide and PAC1 receptors are involved in the anxiogenic action induced by PACAP-38.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
(±)-Propranolol hydrochloride, ≥99% (TLC), powder
Sigma-Aldrich
Atropine sulfate salt monohydrate, ≥97% (TLC), crystalline
Sigma-Aldrich
Haloperidol, powder
USP
Propranolol hydrochloride, United States Pharmacopeia (USP) Reference Standard
USP
Atropine sulfate, United States Pharmacopeia (USP) Reference Standard
Supelco
Atropine Sulfate, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Propranolol hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
(+)-Bicuculline, ≥97.0% (TLC)
USP
Haloperidol, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Phenoxybenzamine hydrochloride, ≥97%, powder
Supelco
(±)-Propranolol hydrochloride, analytical standard
USP
Phenoxybenzamine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Atropine sulfate, European Pharmacopoeia (EP) Reference Standard
Propranolol hydrochloride, European Pharmacopoeia (EP) Reference Standard
Haloperidol, European Pharmacopoeia (EP) Reference Standard
Supelco
Phenoxybenzamine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Haloperidol for peak identification, European Pharmacopoeia (EP) Reference Standard
Haloperidol for system suitability, European Pharmacopoeia (EP) Reference Standard